NOTCH3 and metastatic neoplasm: Consistent with the hypothesis that Notch3 activation promotes early phases of metastatic disease, analysis of a cohort of human serous ovarian cancers revealed that high expression of Notch3IC predicts poor prognosis in stage 1 and stage 2 disease (p = 0.0014; Fig 2B), but not in stage 3 and stage 4 disease (p = 0.11; Fig 2C).